For the Inventor, By the Inventor

Enter assignee name

Seongnam, South Korea

Abl Bio Inc.

Calculating rank

USPTO Granted Patents = 17

EPO Patents = 5

Trademarks = 2

Forward Citations = 13

Loading Chart...

Loading Chart...

108 inventors (with patents filed for the assignee):

Yangsoon Lee (9 out of 10 patents)

Byungje Sung (8 out of 9 patents)

Eunsil Sung (8 out of 9 patents)

4. Yeunju Kim (8 out of 8 patents)

5. Hyejin Chung (8 out of 8 patents)

6. Eunyoung Park (7 out of 8 patents)

7. Youngdon Pak (7 out of 7 patents)

8. Jinhyung Ahn (6 out of 6 patents)

9. Kyungjin Park (6 out of 6 patents)

10. Donghoon Yeom (6 out of 6 patents)

11. Juhee Kim (5 out of 23 patents)

12. Sang Hoon Lee (5 out of 39 patents)

13. Daehae Song (5 out of 5 patents)

14. Yong-Gyu Son (5 out of 5 patents)

15. Jaehyun Eom (5 out of 5 patents)

17 patents: Sort by Forward Citations

1. 12624110 - ANTIBODY TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND RELATED COMPOSITIONS AND USES (2026-05-12),

2. 12577314 - ANTI-BCMA/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),

3. 12252541 - Anti-BCMA antibody and use thereof (2025-03-18),

4. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

5. 12195538 - Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof (2025-01-14),

6. 12195537 - Anti-4-1BB antibody and use thereof (2025-01-14),

7. 12173070 - Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof (2024-12-24),

8. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

9. 12122830 - Anti-ROR1 antibody and use thereof (2024-10-22),

10. 12071483 - Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof (2024-08-27),

11. 12049493 - Anti-alpha-synuclein antibodies and uses thereof (2024-07-30),

12. 11891445 - Anti-B7-H3 antibody and use thereof (2024-02-06),

13. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

14. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

15. 10184010 - Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof (2019-01-22),

Company Overview

Abl Bio Inc. is a biotechnology company based in Seongnam, South Korea, specializing in the development of innovative therapeutics for various diseases. The company focuses on creating monoclonal antibodies and other biologics, leveraging advanced technologies to address unmet medical needs. With a commitment to research and development, Abl Bio aims to enhance treatment options in areas such as oncology and autoimmune disorders, contributing to the advancement of healthcare solutions on a global scale.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

17 Patents

#44 in Seongnam

#719 in South Korea

#35,974 in the World

Seongnam, South Korea

Abl Bio Inc.

Forward Citations = 13

108 inventors:

Yangsoon Lee (9 out of 10 patents)

Byungje Sung (8 out of 9 patents)

Eunsil Sung (8 out of 9 patents)

4. Yeunju Kim (8 out of 8 patents)

5. Hyejin Chung (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abl Bio Inc.. Retrieved from https://idiyas.com/company/abl-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…